» Articles » PMID: 27022018

Regulation of Receptor for Advanced Glycation End Products (RAGE) Ectodomain Shedding and Its Role in Cell Function

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2016 Mar 30
PMID 27022018
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor for advanced glycation end products (RAGE) is a multiligand transmembrane receptor that can undergo proteolysis at the cell surface to release a soluble ectodomain. Here we observed that ectodomain shedding of RAGE is critical for its role in regulating signaling and cellular function. Ectodomain shedding of both human and mouse RAGE was dependent on ADAM10 activity and induced with chemical activators of shedding (ionomycin, phorbol 12-myristate 13-acetate, and 4-aminophenylmercuric acetate) and endogenous stimuli (serum and RAGE ligands). Ectopic expression of the splice variant of RAGE (RAGE splice variant 4), which is resistant to ectodomain shedding, inhibited RAGE ligand dependent cell signaling, actin cytoskeleton reorganization, cell spreading, and cell migration. We found that blockade of RAGE ligand signaling with soluble RAGE or inhibitors of MAPK or PI3K blocked RAGE-dependent cell migration but did not affect RAGE splice variant 4 cell migration. We finally demonstrated that RAGE function is dependent on secretase activity as ADAM10 and γ-secretase inhibitors blocked RAGE ligand-mediated cell migration. Together, our data suggest that proteolysis of RAGE is critical to mediate signaling and cell function and may therefore emerge as a novel therapeutic target for RAGE-dependent disease states.

Citing Articles

RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer.

Magna M, Hwang G, McIntosh A, Drews-Elger K, Takabatake M, Ikeda A NPJ Breast Cancer. 2023; 9(1):59.

PMID: 37443146 PMC: 10344964. DOI: 10.1038/s41523-023-00564-9.


RAGE signaling regulates the progression of diabetic complications.

Taguchi K, Fukami K Front Pharmacol. 2023; 14:1128872.

PMID: 37007029 PMC: 10060566. DOI: 10.3389/fphar.2023.1128872.


Research Advances on the Damage Mechanism of Skin Glycation and Related Inhibitors.

Zheng W, Li H, Go Y, Chan X, Huang Q, Wu J Nutrients. 2022; 14(21).

PMID: 36364850 PMC: 9655929. DOI: 10.3390/nu14214588.


Orally Bioavailable Prodrugs of ψ-GSH: A Potential Treatment for Alzheimer's Disease.

Xie W, Cao B, Zhu H, Raza A, Juckel N, Xie J J Med Chem. 2022; 65(21):14441-14455.

PMID: 36353871 PMC: 9662183. DOI: 10.1021/acs.jmedchem.2c00779.


Role and Therapeutic Potential of RAGE Signaling in Neurodegeneration.

Kinscherf N, Pehar M Curr Drug Targets. 2022; 23(12):1191-1209.

PMID: 35702767 PMC: 9589927. DOI: 10.2174/1389450123666220610171005.


References
1.
Thompson J, Gibson T, Higgins D . Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinformatics. 2008; Chapter 2:Unit 2.3. DOI: 10.1002/0471250953.bi0203s00. View

2.
Suganuma M, Fujiki H, Yoshizawa S, Yasumoto S, Kato Y, Fusetani N . Calyculin A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin. Cancer Res. 1990; 50(12):3521-5. View

3.
Taguchi A, Blood D, Del Toro G, Canet A, Lee D, Qu W . Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000; 405(6784):354-60. DOI: 10.1038/35012626. View

4.
Falcone C, Emanuele E, DAngelo A, Buzzi M, Belvito C, Cuccia M . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005; 25(5):1032-7. DOI: 10.1161/01.ATV.0000160342.20342.00. View

5.
Waterhouse A, Procter J, Martin D, Clamp M, Barton G . Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009; 25(9):1189-91. PMC: 2672624. DOI: 10.1093/bioinformatics/btp033. View